2-((R)-3-oxo-1-tosyl-1,2,3,4-tetrahydroquinoxalin-2-yl)-N-((R)-7-(piperidin-1-ylmethyl)chroman-4-yl)acetamide | 1053196-30-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-((R)-3-oxo-1-tosyl-1,2,3,4-tetrahydroquinoxalin-2-yl)-N-((R)-7-(piperidin-1-ylmethyl)chroman-4-yl)acetamide
• 英文别名: 2-[(2R)-1-(4-methylphenyl)sulfonyl-3-oxo-2,4-dihydroquinoxalin-2-yl]-N-[(4R)-7-(piperidin-1-ylmethyl)-3,4-dihydro-2H-chromen-4-yl]acetamide
• CAS: 1053196-30-7
• 化学式: C₃₂H₃₆N₄O₅S
• 分子量: 588.728
• InChiKey: WQSIOAGGMXCZHW-GGXMVOPNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  42
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  116
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  (R)-7-(piperidin-1-ylmethyl)chroman-4-amine 、 1,2,3,4-tetrahydro-1-[(4-methylphenyl)sulfonyl]-3-oxo-(2R)-2-quinoxalinethanoic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-((R)-3-oxo-1-tosyl-1,2,3,4-tetrahydroquinoxalin-2-yl)-N-((R)-7-(piperidin-1-ylmethyl)chroman-4-yl)acetamide
  参考文献：
  名称：

  Discovery of dihydroquinoxalinone acetamides containing bicyclic amines as potent Bradykinin B1 receptor antagonists

  摘要：

  Replacement of the core P-amino acid in our previously reported piperidine acetic acid and beta-phenylalanine-based Bradykinin B1 antagonists by dihydroquinoxalinone acetic acid increases the in vitro potency and metabolic stability. The most potent compounds from this series have IC(50)s < 0.2 nM in a human B1 receptor functional assay. A molecular modeling study of the binding modes of key compounds, based on a B1 homology model, explains the structure-activity relationship (SAR) for these analogs. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.07.055

文献信息

• Discovery of dihydroquinoxalinone acetamides containing bicyclic amines as potent Bradykinin B1 receptor antagonists
  作者：Jian Jeffrey Chen、Wenyuan Qian、Kaustav Biswas、Vellarkad N. Viswanadhan、Benny C. Askew、Stephen Hitchcock、Randall W. Hungate、Leyla Arik、Eileen Johnson

  DOI：10.1016/j.bmcl.2008.07.055

  日期：2008.8

  Replacement of the core P-amino acid in our previously reported piperidine acetic acid and beta-phenylalanine-based Bradykinin B1 antagonists by dihydroquinoxalinone acetic acid increases the in vitro potency and metabolic stability. The most potent compounds from this series have IC(50)s < 0.2 nM in a human B1 receptor functional assay. A molecular modeling study of the binding modes of key compounds, based on a B1 homology model, explains the structure-activity relationship (SAR) for these analogs. (c) 2008 Elsevier Ltd. All rights reserved.